COST-UTILITY ANALYSIS OF MEPOLIZUMAB VERSUS BENRALIZUMAB FOR SEVERE EOSINOPHILIC ASTHMA IN THE COLOMBIAN HEALTHCARE SYSTEM
Author(s)
Rodríguez E1, García Núncira CY2
1GlaxoSmithKline Colombia, Bogota, Colombia, 2GlaxoSmithKline, Bogota, Colombia
BACKGROUND: Adding mepolizumab to standard treatment with inhaled corticosteroids and controller medications decreases asthma exacerbations and long-term oral corticosteroid use in patients with severe eosinophilic asthma. However, since new biological therapies are available in the Colombian healthcare system, it is necessary to establish their cost-effectiveness to inform local payers and decision-makers. OBJECTIVES: To evaluate the cost-effectiveness of new biologics, mepolizumab and benralizumab, to treat adults with severe eosinophilic asthma in Colombia. METHODS: A Markovian model was used to determine the incremental cost per quality-adjusted life year (QALY) of mepolizumab plus standard of care (SoC) versus benralizumab plus SoC from the payer’s perspective. In a monthly cycle, patients could transition between five health states (three asthma treatment states, asthma related death, and all-cause mortality) and three types of exacerbation events (exacerbations requiring either OCS burst, emergency department visit or hospitalization). Lifetime horizon was used. A network metanalysis (Busse 2019) was used for efficacy data, and local life tables for death probabilities. Costs were estimated following the methods recommended by the local health technology assessment agency. Costs and benefits were discounted at 5% and expressed in 2018 USD (1 USD = 2,956 COP). RESULTS: At the end of the simulation, mean cost of prevention of exacerbations and long-term oral steroid were $69.22 less per patient in mepolizumab, and mean therapy cost was $6,990.0 less per patient in mepolizumab. Treatment with mepolizumab plus SoC and benralizumab plus SoC resulted in 8.97 and 8.73 QALYs respectively. Findings were consistent in the probabilistic sensitivity analysis. CONCLUSIONS: Mepolizumab is a dominating alternative compared with benralizumab in the treatment of adults with severe eosinophilic asthma in Colombia from the payer’s perspective. Funding: GSK (PRJ2813)
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PRS10
Topic
Economic Evaluation, Health Technology Assessment
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Value Frameworks & Dossier Format
Disease
Respiratory-Related Disorders